ATP2A3: A Potential Drug Target and Biomarker (G489)

Target Name: ATP2A3

NCBI ID: G489

ATP2A3

Other Name(s): ATP2A3 variant 4 | ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3, transcript variant 5 | ATP2A3 variant 6 | ATP2A3 variant 2 | Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 (isoform a) | ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3, transcript variant 4 | SERCA3 | ATPase, Ca++ transporting, ubiquitous | Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 | Ca2+-transporting ATPase | ATP2A3 variant 7 | calcium pump 3 | ATP2A3 variant 3 | calcium-translocating P-type ATPase | SR Ca(2+)-ATPase 3 | Adenosine triphosphatase, calcium | ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3, transcript variant 1 | ATP2A3 variant 1 | ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3, transcript variant 7 | Plasma membrane Ca-ATPase | Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 (isoform b) | ATPase, Ca(2+)-transporting, ubiquitous | Sarcoplasmic reticulum ATPase | Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 (isoform e) | Sarco/endoplasmic reticulum Ca2+ -ATPase | ATP2A3 variant 5 | Calcium pump | Sarco/endoplasmic reticulum Ca2+ -ATPase (SERCA3) | Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 (isoform c) | Calcium-translocating P-type ATPase | Ca2+-pumping ATPase | ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3, transcript variant 6 | Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 (isoform f) | Sarco(endo)plasmic reticulum Ca2+-ATPase | AT2A3_HUMAN | Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 (isoform d) | ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 | ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3, transcript variant 3 | adenosine triphosphatase, calcium | Calcium pump 3 | ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3, transcript variant 2 | sarco/endoplasmic reticulum Ca2+ -ATPase

ATP2A3: A Potential Drug Target and Biomarker

ATP (adenosine triphosphate) is a crucial molecule in the process of cell signaling. It is an energy carrier that regulates various cellular processes, including muscle contractions, cell division, and protein synthesis. adenosine triphosphate is synthesized from adenosine, a nucleoside base that contains a phosphate group, and phosphoribosylated RNA (PRPP). The ATP synthase enzyme is responsible for generating ATP from these precursors.

Mutations in the ATP2A3 gene have been linked to various physiological and pathological conditions, including cardiovascular diseases, neurodegenerative diseases, and cancer. The ATP2A3 gene encodes for the protein ATP2A3, which is a key component of the ATP synthase enzyme. The variant 4 of the ATP2A3 gene has been particularly well-studied due to its association with cardiovascular disease.

The ATP2A3 gene has four splice variants, each of which encodes for a different isoform of the ATP synthase enzyme. The most abundant is the ATP2A3 isoform, which is responsible for generating the majority of ATP in the body. The ATP2A3 isoform is composed of 125 amino acid residues and has a calculated molecular mass of 19,312. The ATP2A3 isoform has a single transmembrane domain and a nucleotide kinase catalytic center.

The second-most abundant isoform is the ATP2A3 variant 3 isoform, which is composed of 114 amino acid residues and has a calculated molecular mass of 18,728. The ATP2A3 variant 3 isoform has a single transmembrane domain and a nucleotide kinase catalytic center.

The third-most abundant isoform is the ATP2A3 variant 2 isoform, which is composed of 98 amino acid residues and has a calculated molecular mass of 17,452. The ATP2A3 variant 2 isoform has a single transmembrane domain and a nucleotide kinase catalytic center.

The fourth and least abundant isoform is the ATP2A3 variant 1 isoform, which is composed of 89 amino acid residues and has a calculated molecular mass of 15,976. The ATP2A3 variant 1 isoform has a single transmembrane domain and a nucleotide kinase catalytic center.

The association of the ATP2A3 gene variants with various diseases has led to the search for new drug targets. The variant 4 of the ATP2A3 gene has been shown to be associated with cardiovascular disease, neurodegenerative diseases, and cancer. The variant 4ATP2A3 has been shown to have decreased expression in various tissues, including the heart, brain, and liver, and to have increased expression in the lungs.

The decreased expression of the ATP2A3 variant 4 in various tissues raises the possibility of the variant 4 being a potential drug target. The variant 4ATP2A3 has been shown to have decreased levels of adenosine in various tissues, including the heart, brain, and liver. Adenosine is a potent inhibitor of the activity of the A1 adenosine receptor, which is involved in the regulation of cellular processes including pain perception, inflammation, and sleep.

The decreased levels of adenosine in the variant 4ATP2A3-expressing tissues may contribute to the pathological consequences associated with the variant 4. For example, the decreased adenosine levels may lead to the activation of

Protein Name: ATPase Sarcoplasmic/endoplasmic Reticulum Ca2+ Transporting 3

Functions: This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of calcium. Transports calcium ions from the cytosol into the sarcoplasmic/endoplasmic reticulum lumen. Contributes to calcium sequestration involved in muscular excitation/contraction

The "ATP2A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP2A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets